Sarepta's 84-week data show continued eteplirsen efficacy
This article was originally published in Scrip
Executive Summary
With little new guidance on accelerated US FDA approval for the Duchenne muscular dystrophy (DMD) therapy eteplirsen, Sarepta Therapeutics investors gave the company's stock a 4.3% boost on 19 June based on the next best thing: additional long-term safety and efficacy data for the exon-skipping drug.